公开(公告)号：EP2678014A2

公开(公告)日：2014-01-01

申请号：EP12743551.9

申请日：2012-02-23

申请人： Synta Pharmaceuticals Corp.

发明人： PROIA, David ,  HE, Suqin

IPC分类号： A61K31/4196 ,  A61K31/661 ,  A61K45/06 ,  A61P35/00

CPC分类号： A61K31/4196 ,  A61K31/337 ,  A61K31/661 ,  A61K31/675 ,  A61K45/06 ,  C07D403/10 ,  C07F9/65185 ,  A61K2300/00

摘要： Method for treating a subject with prostate cancer, comprising administering to the an effective amount of a compound represented by the following structural formula: a tautomer, or a pharmaceutically acceptable salt thereof. The variables depicted in the structural formula are defined herein.

公开(公告)号：EP2714038A1

公开(公告)日：2014-04-09

申请号：EP12723814.5

申请日：2012-05-23

申请人： Synta Pharmaceuticals Corp.

发明人： PROIA, David ,  HE, Suqin

IPC分类号： A61K31/4196 ,  A61K31/675 ,  A61P35/00 ,  A61K45/06

CPC分类号： A61K31/4196 ,  A61K31/436 ,  A61K31/4745 ,  A61K31/675 ,  A61K45/06 ,  C07D403/04 ,  A61K2300/00

摘要： A pharmaceutical composition comprising an mTOR/PI3K inhibitor, and an Hsp90 inhibitor according to the following formulae (I) and (Ia) or tautomers, or pharmaceutically acceptable salts thereof, wherein the variables in the structural formulae are defined herein. Also provided are methods for treating a proliferative disorder in a subject in need thereof, using pharmaceutical compositions described herein.

公开(公告)号：EP2849751A1

公开(公告)日：2015-03-25

申请号：EP13724138.6

申请日：2013-05-10

申请人： Synta Pharmaceuticals Corp.

发明人： ACQUAVIVA, Jaime ,  HE, Suqin ,  PROIA, David

IPC分类号： A61K31/4196 ,  A61P35/00

CPC分类号： C07D403/04 ,  A61K31/337 ,  A61K31/4196 ,  A61K31/4545 ,  A61K31/517 ,  A61K39/395 ,  A61K45/06 ,  C07F9/65185 ,  A61K2300/00

摘要： A method for treating cancer with a mutation in ROS or RET, comprising identifying a subject with a cancer with a mutation in ROS or RET, and administering to the subject an effective amount of a compound according to formulae (I) OR (la) or a tautomer, or a pharmaceutically acceptable salt thereof, wherein the variables structural formulae are defined herein.

公开(公告)号：EP2714033A1

公开(公告)日：2014-04-09

申请号：EP12724523.1

申请日：2012-05-25

申请人： Synta Pharmaceuticals Corp.

发明人： PROIA, David ,  HE, Suqin

IPC分类号： A61K31/405 ,  A61K31/4196 ,  A61K31/4535 ,  A61K31/497 ,  A61K31/506 ,  A61K31/519 ,  A61K31/551 ,  A61P35/00

CPC分类号： A61K31/675 ,  A61K31/404 ,  A61K31/405 ,  A61K31/4196 ,  A61K31/4535 ,  A61K31/497 ,  A61K31/506 ,  A61K31/517 ,  A61K31/519 ,  A61K31/551 ,  A61K2300/00

摘要： A pharmaceutical composition comprising a CHK inhibitor, and an Hsp90 inhibitor according to the following formulae or tautomers, or pharmaceutically acceptable salts thereof, wherein the variables in the structural formulae are defined herein. Also provided are methods for treating a proliferative disorder in a subject in need thereof, using pharmaceutical compositions described herein.